NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

FREQ

FREQ US Stock
$9.54
Open: $9.59 High: $9.96 Low: $9.12 Close: $9.18
Range: 2021-04-19 - 2021-04-20
Volume: 1,341,155
Market: Extended-hours
Powered by Finage Stock APIDelayed data
FREQ
  • CEO:
  • Employees:
  • Sector:
  • Industry:
FREQ News
Latest news about the FREQ
  • Are Disappointing Results an Opportunity for Frequency Therapeutics Investors?

    A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?

    View More →
  • Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science

    Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement.

    View More →
  • 3 Beaten-Down Biotech Stocks: Can They Recover?

    The past month has been awfully hard on biotech stocks across the board. Follow-up data for apitegromab didn't set off fireworks as hoped, but an approach that includes a drug that prevents progressive nerve damage for SMA patients seems likely to succeed.

    View More →
  • Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

    Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.

    View More →
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Frequency Therapeutics, Inc. - FREQ

    NEW YORK, NY / ACCESSWIRE / April 8, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ).

    View More →
  • Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Frequency Therapeutics, Inc. (FREQ) Investigation

    NEW YORK, NY / ACCESSWIRE / April 5, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ:FREQ).

    View More →
  • Things Look Grim For Frequency Therapeutics, Inc. (NASDAQ:FREQ) After Today's Downgrade

    Today is shaping up negative for Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders, with the analysts...

    View More →
  • SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 3, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ:FREQ) for violations of the securities laws.

    View More →
  • ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of the securities laws.

    View More →
  • INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

    View More →
  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

    View More →
  • Frequency Therapeutics, Inc. (FREQ) Reports Q4 Loss, Lags Revenue Estimates

    Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of 0.00% and -2.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results

    Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2020.

    View More →
  • Why Frequency Therapeutics Stock Is Crashing Today

    Shares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim results from a phase 2a clinical study evaluating experimental therapy FX-322 in treating sensorineural hearing loss (SNHL). SNHL is the most common form of hearing loss and usually results from damage to auditory sensory hair cells in the inner ear.

    View More →
  • Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss

    Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 in sensorineural hearing loss (SNHL). What Happened: Final results from the Phase 2a study are expected in late Q2 2021. FX-322 is designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with SNHL. The interim results show that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. The four-arm Phase 2a study conducted in 95 subjects demonstrated that while Word Recognition (WR) scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single-injection studies. The interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials. They exceeded well-established published standards, potentially suggesting bias due to trial design. No treatment-related serious adverse events were observed in the study. Why It Matters: The company also announced new data from a parallel study demonstrating hearing improvement from a single injection of FX-322. It plans to advance further development of FX-322 as a single dose regimen. Preliminary results from an open-label, single-dose study of FX-322 in 33 subjects that tested hearing function over the course of 90 days showed 34% of subjects achieved a 10% or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear. The single-dose had a favorable safety profile and was well tolerated. Frequency is also conducting a Phase 1b study in age-related hearing loss. The study's primary objectives are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. The results from the Phase 1b study are expected in Q2 2021. FX-322 Phase 1b study in up to 30 subjects in severe SNHL is also underway, and the results are anticipated in Q3 2021. Price Action: FREQ shares dropped 72.5% at $9.99 in the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaFDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion ApplicationMerck's Keytruda Wins FDA Approval In Esophageal Cancer Settings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen

    Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. Frequency also announced new data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The Company plans to advance further development of FX-322 as a single dose regimen.

    View More →
  • Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?

    Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    View More →
  • Do Options Traders Know Something About Frequency Therapeutics (FREQ) Stock We Don't?

    Investors need to pay close attention to Frequency Therapeutics (FREQ) stock based on the movements in the options market lately.

    View More →
  • What Is The Ownership Structure Like For Frequency Therapeutics, Inc. (NASDAQ:FREQ)?

    A look at the shareholders of Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) can tell us which group is most powerful...

    View More →
  • Earnings Preview: Frequency Therapeutics, Inc. (FREQ) Q4 Earnings Expected to Decline

    Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →